One key finding in the study, according to Seagen's chief medical officer, Roger Dansey, is that adding Tukysa to the regimen showed ... Sankyo's rival HER2 ADC Enhertu (trastuzumab deruxtecan ...

The sponsor should acknowledge that the indication authorized under the NOC/c pathway for Enhertu under control number 285834 can be withdrawn or revised, pending the outcome of Study U306. The ...

In the 557-patient study, Enhertu reduced the risk of disease progression or death by 50%, whilst improving overall survival by 36% compared to chemotherapy – translating to an extra half year ...

Dr. Debu Tripathy breaks down the FDA approval of Enhertu in unresectable or metastatic HR-positive, HER2-low or -ultralow breast cancer. I found community after my metastatic breast cancer diagnosis, ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...